{"entity":{"id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of IOV-4001 in melanoma and non-small-cell lung cancer, run by Iovance Biotherapeutics, Inc., now recruiting.","summary":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is a phase 1/2 interventional study registered as NCT05361174 by Iovance Biotherapeutics, Inc., with 53 participants planned, started 2022-07-20 and due to reach its primary completion in 2027-09. Interventions recorded: IOV-4001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05361174","url":"https://clinicaltrials.gov/study/NCT05361174"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["iovance"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05361174","phase":"1/2","setting":"A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","sponsor":"Iovance Biotherapeutics, Inc.","enrolled":53,"outcomes":[]},"route":"/trials/nct05361174/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/"}]}}